Results 51 to 60 of about 3,987 (159)

Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience

Annals of Medicine
Objectives Benralizumab emerged as a promising treatment option for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the long-term effectiveness and safety of benralizumab in patients with severe asthma and relapsing-refractory ...
Federica Davanzo, Luca Iorio, Marta Codirenzi, Eleonora Fiorin, Gabriella Guarnieri, Alessia Achille, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberto Padoan   +10 more
doaj   +1 more source

Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators

Allergy, EarlyView.
Jaime Bernaola, José Antonio Cañas, Álvaro Arranz‐Fragua, José Manuel Rodrigo‐Muñoz, Daniel Rodríguez‐González, Antonio Serrano‐Santiago, Gema Guillén‐Sánchez, Alma Martínez Fernández, Marcela Valverde‐Monge, Diana Betancor, Erwin Javier Pinillos‐Robles, Claudia Rodríguez‐Busto, María Jesús Rodríguez‐Nieto, Joaquín Sastre, Victoria del Pozo   +14 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Geographic and economic influences on benralizumab prescribing for severe asthma in Japan

Scientific Reports
Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma.
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko   +16 more
doaj   +1 more source

Dissociated Biologic Responses Across the United Airway: A Case Report of Severe Asthma With Chronic Rhinosinusitis With Nasal Polyps and Eosinophilic Otitis Media

Respirology Case Reports, Volume 14, Issue 8, August 2026.
We report a case of severe asthma with chronic rhinosinusitis with nasal polyps and eosinophilic otitis media that was successfully controlled by switching biologic therapy from dupilumab to mepolizumab. Careful monitoring of disease activity and consideration of biologic switching may help achieve optimal control with currently available biologics ...
Tomoko Tajiri, Naoki Takemoto, Toshiya Minakata, Motohiko Suzuki, Yoshiyuki Ozawa, Hirotsugu Ohkubo   +5 more
wiley   +1 more source

Acute Myocarditis: From Pathophysiology to Risk‐Stratified Management—A Clinical Review

European Journal of Clinical Investigation, Volume 56, Issue 8, August 2026.
Stepwise approach to patients with suspected acute myocarditis, integrating the 2024 American College of Cardiology (ACC) four‐stage classification (Stages A–D) and the 2025 European Society of Cardiology (ESC) inflammatory myopericardial syndrome (IMPS) framework. Step 1 (Initial Assessment): clinical presentation, first‐line investigations (ECG, high‐
Michele Golino, Marco Giuseppe Del Buono, Michele Marchetta, Nicola Potere, Aldo Bonaventura, Alessandra Vecchiè, Danilo Malandrino, Giacomo Emmi, Jordana Kron, Antonio Abbate   +9 more
wiley   +1 more source

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results

Journal of Asthma and Allergy, 2019
Gary T Ferguson,1 Jeremy Cole,2 Magnus Aurivillius,3 Paul Roussel,4 Peter Barker,4 Ubaldo J Martin4 On behalf of the GRECO study investigators1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2OK Clinical Research, LLC,
Ferguson GT, Cole J, Aurivillius M, Roussel P, Barker P, Martin UJ   +5 more
doaj  

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

Journal of Asthma and Allergy, 2021
Francesco Menzella,1 Marco Bonavia,2 Matteo Bonini,3 Maria D’Amato,4 Salvatore Lombardo,5 Nicola Murgia,6 Vincenzo Patella,7,8 Massimo Triggiani,9 Girolamo Pelaia10 1Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS,
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G   +8 more
doaj  

Early Intervention With Biologics for Asthma Remission: Promising or Premature?

Respirology, Volume 31, Issue 8, Page 783-786, August 2026.
Santi Nolasco, Jaime Bernaola, Parameswaran Nair   +2 more
wiley   +1 more source

Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial

Allergology International
Background: Biologics are integral in the management of severe asthma. As the effectiveness of the anti-IL-5 receptor antibody benralizumab in Japan remains elusive, this study aimed to assess its real-world effectiveness in Japanese patients with severe
Katsunori Masaki, Maho Suzukawa, Hitoshi Sasano, Norihiro Harada, Yasunari Miyazaki, Hideki Katsura, Etsuko Tagaya, Junko Terada, Masayuki Hojo, Naoya Sugimoto, Hiroyuki Nagase, Yuta Kono, Hisato Hiranuma, Yasuhiro Gon, Ryo Takemura, Misato Irie, Reina Nakamura, Hiroki Kabata, Jun Miyata, Koichi Fukunaga   +19 more
doaj   +1 more source